Asia Pac ECM and Index Rebal, DZT Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Dizal Pharmaceutical / Equity Capital Markets

<ul>
<li>Dizal, a China based commercial stage biopharmaceutical company, is looking to raise at least USD 100 million via an A+H listing. The joint sponsors are GS and Huatai.</li>
<li>In this note, we look at the company’s core innovative products, investor backings and management team.</li>
<li>We also look at its A+H peers and estimate its fair A-H premium for listing.</li>
</ul>


Dizal, a China based commercial stage biopharmaceutical company, is looking to raise at least USD 100 million via an A+H listing. The joint sponsors are GS and Huatai.
In this note, we look at the company’s core innovative products, investor backings and management team.
We also look at its A+H peers and estimate its fair A-H premium for listing.


Dizal (迪哲医药) A+H: Credible Innovative Products